<DOC>
	<DOCNO>NCT00465738</DOCNO>
	<brief_summary>This study investigate efficacy safety incobotulinumtoxinA ( Xeomin ) treatment arm tightness ( upper limb spasticity ) use two different dilution incobotulinumtoxinA ( Xeomin ) .</brief_summary>
	<brief_title>IncobotulinumtoxinA ( Xeomin ) Upper Limb Spasticity</brief_title>
	<detailed_description>IncobotulinumtoxinA ( Xeomin ) botulinum toxin type A preparation free complexing protein . Injected muscle , incobotulinumtoxinA cause reversible local weaken muscle several month , may improve impaired muscle function lessen muscle tightness within day . IncobotulinumtoxinA widely use various severe neurological condition . There evidence treatment effect may influence amount solvent incobotulinumtoxinA dilute injection .</detailed_description>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Main Female male patient ≥ 18 year Stable upper limb spasticity diverse etiology Focal spasticity equal 2 point Ashworth scale wrist flexor Disability Assessment Scale ( DAS ) ≥ 2 point primary therapeutic target screen baseline visit Main Fixed contracture Bilateral upper limb paresis/paralysis Previous treatment BoNT serotype body region within 4 month prior screen Previous plan treatment phenol alcoholinjection target limb Other muscle hypertonia ( e.g . rigidity ) Diagnosis myasthenia gravis , LambertEatonSyndrome , amyotrophic lateral sclerosis , significant neuromuscular disease might interfere study Severe atrophy target limb muscle</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>